Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS

v3.22.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2022
SUBSEQUENT EVENTS  
NOTE 21 - SUBSEQUENT EVENTS

NOTE 20 - SUBSEQUENT EVENTS

 

As of May 12, 2022 the Company issued an aggregate of: (i) 2,073 shares of its common stock for consulting services and valued at $6,400.

 

On May 5, 2022, the Company, entered into a Subscription Agreement with an accredited investor. Pursuant to the Purchase Agreement, the Company to be issued and sold to the Purchaser (i) 110,619 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $2.26 per share and (ii) a warrant to purchase up to 165,929 shares of Common Stock (the “Warrant”). The Warrant has a term of three (3) years and exercise price of $6.00 per share. The aggregate consideration paid to the Company under the Subscription Agreement was $250,000.

 

On April 22, 2022, the Board of Directors of BioCorRx Inc. approved and adopted the BioCorRx Inc. 2022 Omnibus Securities and Incentive Plan. The plan provides for the grant of incentive share options, non qualified share options, performance unit awards, restricted share awards, restricted share unit awards, share appreciation rights, tandem share appreciation rights, unrestricted share awards or any combination of the foregoing to the Company’s employees, directors and consultants. The maximum number of the Company’s shares of common stock, par value $0.001 per share, initially reserved and available for issuance under the 2022 Plan is 695,000 shares.